A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC

Piao, Xuan‐Mei; Byun, Young Ho; Zheng, Chuang-Ming; Song, Sun Jin; Kang, Ho Won; Kim, Dong-Won; Yun, Seok‐Joong

doi:10.3390/cancers15030935

Cited by 7 publications

(6 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A microbiome signature is expected to be identified after extended analysis of stool samples, thereafter allowing manipulation of the microbiota composition for a better treatment outcome. A recent interesting review on the association of the human microbiome with clinical outcomes in RCC has been published by Piao et al [ 75 ] ( Table 1 ).…”

Section: Biological Biomarkers Of Icis Responsementioning

confidence: 99%

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Masson

Thouvenin

Boudier

et al. 2023

Cancers

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) represents around 2% of cancer-related deaths worldwide per year. RCC is an immunogenic malignancy, and treatment of metastatic RCC (mRCC) has greatly improved since the advent of the new immunotherapy agents, including immune checkpoint inhibitors (ICIs). However, it should be stressed that a large proportion of patients does not respond to these therapies. There is thus an urgent need to identify predictive biomarkers of efficacy or resistance associated with ICIs or ICI/Tyrosine kinase inhibitor (TKI) combinations; this is a major challenge to achieve precision medicine for mRCC in routine practice. To identify potential biomarkers, it is necessary to improve our knowledge on the biology of immune checkpoints. A lot of efforts have been made over the last decade in the field of immuno-oncology. We summarize here the main data obtained in this field when considering mRCC. As for clinical biomarkers, clinician and scientific experts of the domain are facing difficulties in identifying such molecular entities, probably due to the complexity of immuno-oncology and the constant adaptation of tumor cells to their changing environment.

show abstract

Section: Biological Biomarkers Of Icis Responsementioning

confidence: 99%

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Masson

Thouvenin

Boudier

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The 2016 World Health Organization (WHO) classification identified distinct subtypes within RCC, each characterised by specific genetic and histopathological features. These include clear cell RCC (comprising 70-80% of cases), papillary RCC (10-15%), and chromophobe RCC (4-5%) [254]. Approximately two-thirds of RCC cases are localised, and the standard treatment involves complete surgical tumour resection [255].…”

Section: Gut Dysbiosis In Renal Cell Carcinoma (Rcc)mentioning

confidence: 99%

The Gut–Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics

Saxami,

Kerezoudi,

Eliopoulos

et al. 2023

Life

View full text Add to dashboard Cite

The human gut microbiota (GM) is a complex microbial ecosystem that colonises the gastrointestinal tract (GIT) and is comprised of bacteria, viruses, fungi, and protozoa. The GM has a symbiotic relationship with its host that is fundamental for body homeostasis. The GM is not limited to the scope of the GIT, but there are bidirectional interactions between the GM and other organs, highlighting the concept of the “gut–organ axis”. Any deviation from the normal composition of the GM, termed ”microbial dysbiosis”, is implicated in the pathogenesis of various diseases. Only a few studies have demonstrated a relationship between GM modifications and disease phenotypes, and it is still unknown whether an altered GM contributes to a disease or simply reflects its status. Restoration of the GM with probiotics and prebiotics has been postulated, but evidence for the effects of prebiotics is limited. Prebiotics are substrates that are “selectively utilized by host microorganisms, conferring a health benefit”. This study highlights the bidirectional relationship between the gut and vital human organs and demonstrates the relationship between GM dysbiosis and the emergence of certain representative diseases. Finally, this article focuses on the potential of prebiotics as a target therapy to manipulate the GM and presents the gaps in the literature and research.

show abstract

“…Ландшафт системной терапии метастатического светло клеточного рака почки претерпевает стремительные изменения, в первую очередь за счет внедрения в клиническую практику новых эффективных комбинаций препаратов, которые постепенно вытесняют старые тирозинкиназные ингибиторы [1]. Актуальные на момент написания статьи клинические рекомендации различных отечественных и зарубежных профессиональных сообществ однозначно указывают в качестве варианта выбора первой линии терапии метастатического светлоклеточного рака почки комбинированные режимы вне зависимости от группы прогноза пациента (табл.…”

Section: Introductionunclassified

Treatment of metastatic сlear cell renal cell carcinoma: focus on a group of patients with favourable prognosis

Rumyantsev

2024

Medicinskij sovet

View full text Add to dashboard Cite

Current clinical guidelines of various domestic and foreign professional communities indicate combination regimens as an option for the first-line therapy for metastatic сlear cell renal cell carcinoma, regardless of the patient’s prognosis group. This review article is devoted to the analysis of the current evidence base for the use of different variants of combination therapy regimens in patients with metastatic renal cell carcinoma and assessment of the role of single-component cancer therapy options in the initial treatment of this disease. We reviewed the results of studies of current immuno-oncology therapy regimens in the first-line renal cell carcinoma therapy with a focus on a favourable prognosis group, taking into account the latest updates from the studies evaluating the efficacy of combination treatments (pembrolizumab/axitinib, pembrolizumab/lenvatinib, nivolumab/cabozantinib, avelumab/axitinib). We found that although the use of certain combinations of immunooncology and targeted drugs give better results of disease control, objective response and progression-free survival rates, none of the studied combinations to date has shown a significant increase in overall patient survival rates, which is a key treatment efficacy indicator in metastatic cancer. Conclusions drawn from this review indicate that monotherapy with tyrosine kinase inhibitors, such as sunitinib or pazopanib, appears to be sufficient and optimal from a clinical and economic point of view in the treatment of a favourable prognosis group. For patients with a favourable prognosis, tyrosine kinase inhibitor monotherapy may be a primary rather than an alternative therapeutic option until the benefit of combinations in terms of overall survival rates has been showed.

show abstract

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC

Cited by 7 publications

References 83 publications

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

The Gut–Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics

Treatment of metastatic сlear cell renal cell carcinoma: focus on a group of patients with favourable prognosis

Contact Info

Product

Resources

About